Special Issue "Recent Advances in Drug Discovery Based on β-Glucans"
Deadline for manuscript submissions: 28 February 2023 | Viewed by 114
Interests: bioactive compound extraction; metabolic syndrome; bioactive polysaccharides; phenolic compounds; biological rhythms; mushrooms
Special Issues, Collections and Topics in MDPI journals
β-glucans constitute a highly diverse group of polysaccharides composed of β-linked glucose monomers that can be mainly found in plants, fungi, bacteria, and seaweed cell walls. In addition to the different nature of the sources, their particular structure is varied depending on the specific linkages (β 1,3, β 1,4, β 1,6), the branching and polymerization degree, the molecular weight, etc. In recent decades, interest in these molecules has noticeably increased because of their relevant biological activities that have led to a plethora of studies to develop novel drugs and food supplements based on β-glucans. Among these bioactivities, hypocholesterolemic ability has been described by reducing cholesterol intestinal absorption, scavenging bile acids, or stimulating microbiota short-fatty acid production. Moreover, a potent immune-modulatory action has been observed for β-glucans, being associated in many cases with anti-inflammatory and antitumoral activities. In addition, antimicrobial, antiviral, antioxidant, and wound-healing effects have been reported. In this sense, pharmaceutical approaches have been carried out exploring the effectiveness of β-glucans considering administration routes, side effects, mechanisms of actions, etc. The versatility of these polysaccharides places them not only as active ingredients but also as biodegradable carriers for other bioactive compounds targeting controlled release and bioavailability enhancement. The aim of this Special Issue is to investigate the latest findings and insights related to β-glucans-based drugs and supplements and to elucidate future perspectives.
Dr. Diego Morales
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune system
- novel drugs